Multi-functional Nanocarrier against Canine Lymphoma
抗犬淋巴瘤的多功能纳米载体
基本信息
- 批准号:8247714
- 负责人:
- 金额:$ 59.62万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-04-01 至 2015-01-31
- 项目状态:已结题
- 来源:
- 关键词:AbraxaneAcidsAdverse drug effectAnimalsAvastinB-Cell LymphomasB-LymphocytesBiodistributionBortezomibBreastCancer PatientCanis familiarisCell surfaceChargeCombination Drug TherapyCompanionsCytotoxic agentDNADevelopmentDisseminated Malignant NeoplasmDoxorubicinDrug Delivery SystemsDrug FormulationsDrug KineticsExhibitsFDA approvedGefitinibImageIn VitroIntercalating AgentsLabelLeadLibrariesLigandsLymphomaMalignant NeoplasmsMaximum Tolerated DoseMethodsMicellesMicroscopyModelingMusNon-Hodgkin&aposs LymphomaOrganOvarianPaclitaxelParticle SizePatientsPharmaceutical PreparationsPhasePhase I Clinical TrialsPolymersPropertyProteasome InhibitorRadioisotopesRadiolabeledRattusReportingResearchScreening procedureShapesSiteSolid NeoplasmSurfaceTherapeuticTherapeutic AgentsToxic effectTransgenic MiceTreatment EfficacyUnited StatesVelcadeVincristineXenograft Modelanalogbasecancer typecell typecombinatorialdesignin vivoinhibitor/antagonistmulticatalytic endopeptidase complexnanonanocarriernanoformulationnanoparticlenanotherapeuticnanotherapyneoplastic cellnoveloptical imagingpublic health relevanceradiotracertheranosticstumoruptake
项目摘要
DESCRIPTION (provided by applicant): The multifunctional micelle-based targeting nanotherapeutics to be developed in this project offer an opportunity to deliver high concentration of cytotoxic drugs (e.g. doxorubicine), molecularly targeted drugs (e.g. bortezomib [Velcade(R)], a proteosome inhibitor) as well as therapeutic radionuclides such as 131I to the tumor sites while sparing normal organs, thus greatly enhance the anti-tumor effects and lessen the systemic side effects of these drugs. As a result, we expect patients with advanced non- Hodgkin lymphoma (both T- and B-cell type) or solid tumors will benefit from such novel nanotherapies. In addition, such multifunctional nanoplatform can also be used as tumor imaging agents. Our nanotherapeutic platform is unique and comprised of oligocholic acid based micelles with drugs loaded inside and cancer targeting ligands decorating the micelle surface. We believe the addition of LLP2A, a lymphoma targeting ligand, to the nanotherapeutics can facilitate the intracellular delivery of the nanocarrier to the tumor cells in vivo and therefore will greatly enhance their anti-tumor efficacies. In this proposed research, biodistribution properties (imaging) and therapeutic efficacies of such targeting nanoparticles will be evaluated in both transgenic mouse lymphoma models and spontaneous canine lymphoma. This research will lead to the development of more efficacious and less toxic multifunctional targeting nanoformulations of bortexomib (a proteasome inhibitor), doxorubicin (a DNA intercalate), and therapeutic radionuclide 131I, all of which are expected to be useful in the treatment of many cancer types including non-Hodgkin lymphoma (NHL). If successful, this therapeutic approach can be applied to many other cancer types as well and therefore will have a great impact in the survival of cancer patients in the United States and around the world.
PUBLIC HEALTH RELEVANCE: The multifunctional micelle-based targeting nanotherapeutics to be developed in this project offer an opportunity to deliver high concentration of cytotoxic drugs, molecularly targeted drugs as well as therapeutic radionuclides such as 131I to the tumor sites while sparing normal organs, thus greatly enhance the anti-tumor effects and lessen the systemic side effects of these drugs. Amphiphilic polymers will be designed, synthesized, and optimized for efficient loading of bortezomib or doxorubicin to form nanoparticles. These nanotherapeutics will be evaluated for their anti-tumor efficacies in transgenic mouse lymphoma model and in companion dogs with spontaneous lymphomas.
描述(由申请人提供):本项目将开发的多功能基于胶束的靶向纳米治疗药物提供了输送高浓度细胞毒性药物(例如阿霉素)、分子靶向药物(例如硼替佐米 [Velcade(R)]、一种蛋白酶体)的机会。抑制剂)以及131I等治疗性放射性核素到达肿瘤部位,同时不伤害正常器官,从而大大增强抗肿瘤作用作用并减轻这些药物的全身副作用。因此,我们预计晚期非霍奇金淋巴瘤(T 细胞型和 B 细胞型)或实体瘤患者将从此类新型纳米疗法中受益。此外,这种多功能纳米平台还可以用作肿瘤成像剂。 我们的纳米治疗平台是独特的,由寡胆酸基胶束组成,内部装有药物,胶束表面装饰有癌症靶向配体。我们相信,在纳米治疗药物中添加淋巴瘤靶向配体LLP2A可以促进纳米载体在体内递送至肿瘤细胞,从而大大增强其抗肿瘤功效。在这项拟议的研究中,将在转基因小鼠淋巴瘤模型和自发性犬淋巴瘤模型中评估此类靶向纳米粒子的生物分布特性(成像)和治疗效果。 这项研究将导致开发更有效、毒性更低的多功能靶向纳米制剂,包括硼替索米(一种蛋白酶体抑制剂)、阿霉素(一种 DNA 嵌入物)和治疗性放射性核素 131I,所有这些药物预计将可用于治疗许多癌症类型包括非霍奇金淋巴瘤(NHL)。如果成功,这种治疗方法也可以应用于许多其他癌症类型,因此将对美国和世界各地癌症患者的生存产生巨大影响。
公共健康相关性:本项目将开发的多功能胶束靶向纳米治疗药物提供了将高浓度的细胞毒性药物、分子靶向药物以及 131I 等治疗性放射性核素输送到肿瘤部位的机会,同时不伤害正常器官,从而极大地改善肿瘤部位的治疗效果。增强抗肿瘤作用并减轻这些药物的全身副作用。两亲性聚合物将被设计、合成和优化,以有效负载硼替佐米或多柔比星以形成纳米颗粒。这些纳米疗法将在转基因小鼠淋巴瘤模型和患有自发性淋巴瘤的伴侣犬中评估其抗肿瘤功效。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KIT S LAM其他文献
KIT S LAM的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KIT S LAM', 18)}}的其他基金
A Mannose 6-Phosphate Decorated Transformable Nanoplatform for Targeted Uptake in HER2+ Tumors
用于 HER2 肿瘤靶向摄取的甘露糖 6-磷酸盐修饰的可转化纳米平台
- 批准号:
10381225 - 财政年份:2021
- 资助金额:
$ 59.62万 - 项目类别:
HER2-targeting transformable nanotherapeutic platform against HER2+ cancers
针对 HER2 癌症的可转化纳米治疗平台
- 批准号:
10524157 - 财政年份:2020
- 资助金额:
$ 59.62万 - 项目类别:
HER2-targeting transformable nanotherapeutic platform against HER2+ cancers
针对 HER2 癌症的可转化纳米治疗平台
- 批准号:
10737741 - 财政年份:2020
- 资助金额:
$ 59.62万 - 项目类别:
HER2-targeting transformable nanotherapeutic platform against HER2+ cancers
针对 HER2 癌症的可转化纳米治疗平台
- 批准号:
10348732 - 财政年份:2020
- 资助金额:
$ 59.62万 - 项目类别:
HER2-targeting transformable nanotherapeutic platform against HER2+ cancers
针对 HER2 癌症的可转化纳米治疗平台
- 批准号:
10553132 - 财政年份:2020
- 资助金额:
$ 59.62万 - 项目类别:
The rodent eye as a non-invasive window for understanding cancer nanotherapeutics
啮齿动物的眼睛是了解癌症纳米疗法的非侵入性窗口
- 批准号:
9751792 - 财政年份:2015
- 资助金额:
$ 59.62万 - 项目类别:
Genetically encoded reporters of integrated neural activity for functional mapping of neural circuitry
综合神经活动的基因编码报告器,用于神经回路的功能映射
- 批准号:
9130272 - 财政年份:2014
- 资助金额:
$ 59.62万 - 项目类别:
Genetically encoded reporters of integrated neural activity for functional mapping of neural circuitry
综合神经活动的基因编码报告器,用于神经回路的功能映射
- 批准号:
8934232 - 财政年份:2014
- 资助金额:
$ 59.62万 - 项目类别:
相似国自然基金
琥珀酸代谢重编逆转碳青霉烯耐药铜绿假单胞菌耐药性的研究
- 批准号:32370191
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
植物特有蛋白FENT响应脱落酸信号调控囊泡运输的分子机制研究
- 批准号:32370329
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
钽铌酸钾晶体多效应耦合及光场调控极化序构的电光性能增益机制研究
- 批准号:62305089
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
中性氨基酸转运体SNAT2在血管稳态和重构中的作用及机制
- 批准号:82370423
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
基于胆汁酸介导的TGR5/GLP-1环路探究解毒通络调肝方调控肠肝轴改善T2DM-IR作用机制
- 批准号:82374380
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
相似海外基金
A Creative Integration of Omega-3 Fatty Acids into Pancreatic Cancer Chemotherapy
将 Omega-3 脂肪酸创造性地整合到胰腺癌化疗中
- 批准号:
8824063 - 财政年份:2015
- 资助金额:
$ 59.62万 - 项目类别:
A Creative Integration of Omega-3 Fatty Acids into Pancreatic Cancer Chemotherapy
将 Omega-3 脂肪酸创造性地整合到胰腺癌化疗中
- 批准号:
8991305 - 财政年份:2015
- 资助金额:
$ 59.62万 - 项目类别: